Madrigal Pharmaceuticals, Inc. MDGL Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s retained earnings?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported retained earnings of -$2.18B in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s retained earnings decreased by 16.5% year-over-year, from -$1.88B to -$2.18B.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s retained earnings has grown at a 37.5% compound annual growth rate (CAGR), from -$425.46M to -$2.09B.
- What does retained earnings mean?
- The cumulative profit or loss the company has generated since its founding.
- How do you interpret retained earnings?
- A growing negative balance is expected for pre-revenue biotechs; a positive trend indicates transition to profitability.
- How does retained earnings compare across companies?
- Typically negative for early-stage clinical biotechs; positive for mature commercial-stage firms.